p73介导的化学敏感性：致癌突变型p53的优先作用靶点。 - Suppr

Suppr

超能文献

p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53.

作者信息

Strano Sabrina, Blandino Giovanni

机构信息

Department of Experimental Oncology, Regina Elena Cancer Institute, 00158-Rome, Italy.

出版信息

Cell Cycle. 2003 Jul-Aug;2(4):348-9.

PMID:12851488

Abstract

摘要

相似文献

p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53.

Cell Cycle. 2003 Jul-Aug;2(4):348-9.

p53 family members: similar biochemistry, different biology.

Cancer Biol Ther. 2005 Apr;4(4):419-20. doi: 10.4161/cbt.4.4.1760. Epub 2005 Apr 27.

p63 and p73: roles in development and tumor formation.

Mol Cancer Res. 2004 Jul;2(7):371-86.

P53 family activities in development and cancer: relationship to melanocyte and keratinocyte carcinogenesis.

J Invest Dermatol. 2005 Nov;125(5):857-64. doi: 10.1111/j.0022-202X.2004.23920.x.

Brothers in arms against cancer.

Science. 2011 Mar 25;331(6024):1551-2. doi: 10.1126/science.331.6024.1551.

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.

J Clin Invest. 2011 Feb;121(2):809-20. doi: 10.1172/JCI43897.

Functional regulation of p73 and p63: development and cancer.

Trends Biochem Sci. 2003 Dec;28(12):663-70. doi: 10.1016/j.tibs.2003.10.004.

The p53 family: same response, different signals?

Mol Med Today. 1999 Sep;5(9):387-92. doi: 10.1016/s1357-4310(99)01545-2.

p73: a complex gene for building a complex brain.

Cell Cycle. 2011 Apr 15;10(8):1188-9. doi: 10.4161/cc.10.8.15297.

From p63 to p53 across p73.

FEBS Lett. 2001 Feb 16;490(3):163-70. doi: 10.1016/s0014-5793(01)02119-6.

引用本文的文献

p53 signaling in cancer progression and therapy.

Cancer Cell Int. 2021 Dec 24;21(1):703. doi: 10.1186/s12935-021-02396-8.

Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.

Cancers (Basel). 2021 Oct 26;13(21):5362. doi: 10.3390/cancers13215362.

Cancer Stemness: p53 at the Wheel.

Front Oncol. 2021 Jan 11;10:604124. doi: 10.3389/fonc.2020.604124. eCollection 2020.

New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

J Exp Clin Cancer Res. 2018 Feb 15;37(1):30. doi: 10.1186/s13046-018-0705-7.

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Int J Mol Sci. 2017 May 3;18(5):961. doi: 10.3390/ijms18050961.

Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Front Oncol. 2016 Mar 31;6:77. doi: 10.3389/fonc.2016.00077. eCollection 2016.

microRNAs: short non-coding bullets of gain of function mutant p53 proteins.

Oncoscience. 2014 Jun 7;1(6):427-33. doi: 10.18632/oncoscience.52. eCollection 2014.

Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.

Genes Cancer. 2012 Jul;3(7-8):491-502. doi: 10.1177/1947601912462719.

p53 mutations in cancer.

Nat Cell Biol. 2013 Jan;15(1):2-8. doi: 10.1038/ncb2641.

p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.

Arch Biochem Biophys. 2012 Feb 1;518(1):79-88. doi: 10.1016/j.abb.2011.12.006. Epub 2011 Dec 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53.

Cell Cycle. 2003 Jul-Aug;2(4):348-9.

p53 family members: similar biochemistry, different biology.

Cancer Biol Ther. 2005 Apr;4(4):419-20. doi: 10.4161/cbt.4.4.1760. Epub 2005 Apr 27.

p63 and p73: roles in development and tumor formation.

Mol Cancer Res. 2004 Jul;2(7):371-86.

P53 family activities in development and cancer: relationship to melanocyte and keratinocyte carcinogenesis.

J Invest Dermatol. 2005 Nov;125(5):857-64. doi: 10.1111/j.0022-202X.2004.23920.x.

Brothers in arms against cancer.

Science. 2011 Mar 25;331(6024):1551-2. doi: 10.1126/science.331.6024.1551.

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.

J Clin Invest. 2011 Feb;121(2):809-20. doi: 10.1172/JCI43897.

Functional regulation of p73 and p63: development and cancer.

Trends Biochem Sci. 2003 Dec;28(12):663-70. doi: 10.1016/j.tibs.2003.10.004.

The p53 family: same response, different signals?

Mol Med Today. 1999 Sep;5(9):387-92. doi: 10.1016/s1357-4310(99)01545-2.

p73: a complex gene for building a complex brain.

Cell Cycle. 2011 Apr 15;10(8):1188-9. doi: 10.4161/cc.10.8.15297.

From p63 to p53 across p73.

FEBS Lett. 2001 Feb 16;490(3):163-70. doi: 10.1016/s0014-5793(01)02119-6.

引用本文的文献

p53 signaling in cancer progression and therapy.

Cancer Cell Int. 2021 Dec 24;21(1):703. doi: 10.1186/s12935-021-02396-8.

Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.

Cancers (Basel). 2021 Oct 26;13(21):5362. doi: 10.3390/cancers13215362.

Cancer Stemness: p53 at the Wheel.

Front Oncol. 2021 Jan 11;10:604124. doi: 10.3389/fonc.2020.604124. eCollection 2020.

New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

J Exp Clin Cancer Res. 2018 Feb 15;37(1):30. doi: 10.1186/s13046-018-0705-7.

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Int J Mol Sci. 2017 May 3;18(5):961. doi: 10.3390/ijms18050961.

Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Front Oncol. 2016 Mar 31;6:77. doi: 10.3389/fonc.2016.00077. eCollection 2016.

microRNAs: short non-coding bullets of gain of function mutant p53 proteins.

Oncoscience. 2014 Jun 7;1(6):427-33. doi: 10.18632/oncoscience.52. eCollection 2014.

Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.

Genes Cancer. 2012 Jul;3(7-8):491-502. doi: 10.1177/1947601912462719.

p53 mutations in cancer.

Nat Cell Biol. 2013 Jan;15(1):2-8. doi: 10.1038/ncb2641.

p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity.

Arch Biochem Biophys. 2012 Feb 1;518(1):79-88. doi: 10.1016/j.abb.2011.12.006. Epub 2011 Dec 16.